Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence

Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence

Treatment of neuroendocrine tumours (NETs) with radioligand therapy (RLT) for example, 177Lu‐DOTATATE is generally well‐tolerated and prolongs time to progression in most patients. However, approximately 20% of patients are nonresponders. In addition, complete responses are rare (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuroendocrinology 2022-11, Vol.34 (11), p.e13208-n/a
Hauptverfasser: Navalkissoor, Shaunak, Gnanasegaran, Gopinath, Grossman, Ashley
Format: Artikel
Sprache:eng
Schlagworte:
alpha particles
Biomarkers
Humans
Neuroendocrine tumors
Neuroendocrine Tumors - drug therapy
Neuroendocrine Tumors - pathology
Neuroendocrine Tumors - radiotherapy
neuroendocrine tumours
Patients
peptide receptor radionuclide
Radiopharmaceuticals - therapeutic use
Somatostatin
Somatostatin receptors
therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment of neuroendocrine tumours (NETs) with radioligand therapy (RLT) for example, 177Lu‐DOTATATE is generally well‐tolerated and prolongs time to progression in most patients. However, approximately 20% of patients are nonresponders. In addition, complete responses are rare (
ISSN:0953-8194
1365-2826
DOI:10.1111/jne.13208